REINACH and BASEL, Switzerland, September 21 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) presented several preclinical studies on its novel topical antibiotic AR-2474 at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. ICAAC is a major scientific conference where thousands of scientists and clinicians from all over the world gather to discuss the latest developments in the field of infectious diseases.
AR-2474 is a novel synthetic antibacterial currently under development for topical indications including treatment of infections and prevention of transmission of the "superbug" MRSA. AR-2474 is a diphenyl urea with unique properties.
F1-2100: The topical activity and potency of AR-2474 was compared with the gold standard mupirocin (Bactroban(R)) in two preclinical models of MRSA infection of the skin and of nasal decolonisation. In both models, a preliminary topical formulation of AR-2474 was demonstrated to be as efficacious as mupirocin.
F1-2094, F1-2095, F1-2096, F1-2097, F1-2100A: The in vitro microbiological activity of AR-2474 and of other compounds of the class was assessed in-house and by leading laboratories against large panels of clinical isolates. AR-2474 showed potent activity against methicillin susceptible and resistant staphylococci including nosocomial and community S. aureus isolates. Importantly, AR-2474 exhibits no cross-resistance with other classes of currently used topical treatments. The compound also exhibited potent activity against Group A and B streptococci, enterococci, pneumococci and other important pathogens responsible for causing infections of the skin, eye and mouth.
F1-2099: AR-2474 demonstrated little or no propensity for resistance development. No resistant mutants to AR-2474 could be selected using different methodologies.
F1-2098: The data showed that AR-2474 is bactericidal, exhibits a post
antibiotic effect and shows no antagonism wi
|SOURCE Arpida Ltd.|
Copyright©2007 PR Newswire.
All rights reserved